IRadimed (IRMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Friday, July 31, 2026 at 11:00 a.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer - Roger Susi
• Chief Financial Officer - John Glenn

TAKEAWAYS

• Revenue -- $20.5 million, representing a 0.5% increase from $20.4 million in the second quarter of 2025.
• GAAP Diluted EPS -- $0.41, compared to $0.45 in the prior year period.
• Non-GAAP Diluted EPS -- $0.46, reflecting the exclusion of stock-based compensation expense.
• Gross Margin -- 74%, declining from 78% in the second quarter of 2025 due to higher manufacturing costs and inefficiencies associated with the first production ramp of the 3870 pump.
• MRI Compatible Patient Monitor Revenue -- $6.7 million, representing 12% growth year over year.
• Ferro-magnetic Detection System Revenue -- $0.8 million, an increase of 57% year over year.
• Disposable Revenue -- $4.8 million, growing 14% due to increased device utilization.
• 3870 Pump Production -- 130 to 135 units, meeting the manufacturing target for the first general release production cycle.
• Q3 3870 Production Target -- Over 300 units, as the company plans to more than double output to address building backlog.
• Quad System Mix -- 70%, representing the proportion of older two-channel systems being replaced with the new four-channel quad pump configurations.
• Quad System Average Selling Price -- $110,000, providing a lift of more than 20% in the average selling price per pump.
• Domestic Sales -- 82% of total revenue, compared to 89% in the second quarter of 2025 when domestic legacy pump revenue was exceptionally high.
• Operating Expenses -- $8.8 million, a 4% decrease compared to $9.2 million in the second quarter of 2025.
• General and Administrative Expense -- $3.9 million, down 10% primarily due to lower legal, professional, and payroll fees.
• Sales and Marketing Expense -- $4.2 million, up 6% driven by higher sales commissions from strong quarterly bookings.
• Research and Development Expense -- $0.7 million, down 25% reflecting an increase in capitalized internal software development for next-generation monitors.
• GAAP Net Income -- $5.2 million, compared to $5.8 million in the second quarter of 2025.
• Cash and Cash Equivalents -- $59.1 million as of June 30, 2026, up from $51.2 million at the end of fiscal 2025.
• Operating Cash Flow -- $14.2 million for the first six months of 2026, an 18% increase compared to the first half of 2025.
• Quarterly Cash Dividend -- $0.20 per share, declared by the Board of Directors and payable on Aug. 28, 2026.
• Q3 2026 Revenue Guidance -- $23 million to $24.5 million.
• Q3 2026 Non-GAAP EPS Guidance -- $0.54 to $0.59.
• Full Year 2026 Revenue Guidance -- $91 million to $96 million, which management reaffirmed during the call.
• Full Year 2026 Non-GAAP EPS Guidance -- $2.09 to $2.24.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

• Susi stated, "Q3 will remain a stretch as we plan to more than double production again to over 300 units," indicating potential operational strain during the rapid manufacturing scale-up.
• Glenn noted that the gross margin decline to 74% "reflects the higher manufacturing costs associated with our first sizable production ramp of the 3870," identifying start-up inefficiencies as a drag on profitability.

SUMMARY

Management reported that IRadimed Corporation (NASDAQ:IRMD) reached its manufacturing targets for the new 3870 MR IV pump system, transitioning from a standing start to a general release production of 130 to 135 units. The company reported a shift in product mix toward four-channel quad systems, which accounted for a majority of replacement orders and contributed to a significant increase in average selling prices. While the production ramp introduced temporary manufacturing inefficiencies that compressed gross margins, the company reaffirmed its full-year 2026 guidance and maintained a positive outlook for production scaling and cost normalization through the second half of the year. Financial results included steady growth in patient monitoring and disposables, alongside a dividend increase and a growing cash position.

• CEO Susi attributed the gross margin compression to the "manufacturing learning curve," noting that start-up costs are expected to be reduced by more than 50% in the third quarter.
• Management confirmed that bookings for the new 3870 pump were more than double the number of units shipped during the quarter.
• Susi identified a domestic replacement opportunity of 6,400 older 3860 pump channels, targeting an additional 1,000 channel sales per year through this replacement cycle.
• The company reported a record high for domestic monitor sales, with 71 units booked during the quarter while maintaining high average selling prices.
• Glenn indicated that the effective tax rate is expected to remain in the 24% range for the rest of the year, following adjustments to windfall deductions tied to equity grants.
• Management noted that lead times for new systems may extend to four to six months as production ramps to meet current demand levels.

INDUSTRY GLOSSARY

• 3870 MR IV: A next-generation MRI-compatible intravenous infusion pump system designed for use in high-magnetic-field environments.
• Quad Pump: A four-channel configuration of the 3870 pump system, allowing for simultaneous delivery of multiple fluids.
• Ferro-magnetic Detection System (FMD): A safety system used to identify magnetic objects before they enter the MRI scanner room to prevent accidents.
• MRidium: The brand name for IRadimed's MRI-compatible IV infusion pump products.
• 510(k): A regulatory clearance from the FDA that allows a medical device to be marketed in the United States.

Full Conference Call Transcript

Operator: Hello, and welcome to the IRadimed Corporation's Second Quarter of 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, July 31, 2026, and contains time-sensitive accurate information that is valid only for today. Earlier IRadimed released its financial results for the second quarter of 2026. A copy of this press release announcing the company's earnings is available under the headings News on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live on the company's website at iradimed.com, and a replay will be available there for the next 90 days.

Some of the information in today's section will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans and events and may include the company's expected future results. IRadimed reminds you that future results may differ materially from these forward-looking statements due to severe risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section in the company's most recent report filed with the Securities and Exchange Commission, which may obtain free from the SEC's website at sec.gov.

I want to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi?

Roger Susi: Thank you, operator. Good morning, and welcome to IRadimed Corp's Second Quarter 2026 Earnings Call. This quarter, we embarked on the first general release production of the new 3870 MR IV pump system as planned, targeting, as discussed last quarter, the building of 130 to 135 of these new pumps. I'm very pleased to report that our teams performed exceptionally well and achieved our manufacturing target, no small task. Taking 3870 production from a standing start to an impressive rate in the quarter. Those efforts with those efforts, we were able to achieve revenue and earnings per our guidance with revenue of $20.5 million and earnings of $0.41 on a GAAP basis and non-GAAP earnings of $0.46 per share.

As we expected and guided. The new pump launch consumes significant effort, including increased labor and overhead expenses, much of which is reflected in the quarter's gross margin of 74%. I want to speak to what's next, and that starts with a discussion of how bookings were in the quarter, how fast we can continue to ramp the new 3870 pump production and a short recap of our opportunity.

Opportunities for the new 3870 pump system are both the increased penetration of the greenfield which are predominantly those facilities that continue to deal with IV fluid delivery in the MR setting via the various old school workarounds, expansion of current customer use requiring more pumps, as well as the quite substantial replacement of IRadimed aged installed base of 3860 pump systems. The most immediate and significant increase coming from the large replacement opportunity. This replacement opportunity will be our key growth driver for the next several years and was indeed a significant factor for many of the orders booked in the second quarter.

Recalling that for the U.S. market, there are approximately 6,400 5-plus year old 3860/61 pump channels up for replacement, we had been selling approximately 1,100 such 3860 channels annually. And with the new 3870, we target adding another 1,000 channels per year through replacement sales of those -- from those existing 6,400 old 3860 units that are over 5 years old. Bookings for the quarter were more than double the units shipped showing very strong customer acceptance and quick decision-making while only scratching this -- at the target replacement based mildly.

Add to this that not only are we replacing those older 2-channel pump systems, but an astounding 70% of those were replaced with our 4-channel quad pump system, thus requiring twice the number of pumps. Additionally, the ASP of this quad systems has been north of $110,000, providing well over a 20% lift in the ASP per pump. In short, the demand is exceeding our expectations in both the number of pumps and the ASP. But there's also some fantastic news with our patient monitor. Though the sales team was quite busy obtaining orders for the new 3870, they outperformed themselves and brought in a record high of 71 monitors from the domestic market while maintaining a high ASP.

With a strong backlog and the sales potential we have, it comes down to the ramp-up of production and the ramp down of costs associated with manufacturing learning curve, which we've all been climbing every day. Q2 was a huge effort with plenty of inefficiencies and costs as we went from 0 to 130-plus 3870 pumps. Q3 will remain a stretch as we plan to more than double production again to over 300 units. However, we see that we are indeed riding that learning curve well and taming it, so we expect that the start-up costs experienced in Q2 will be better than 50% reduced in Q3, while earnings will reflect such a strong positive move as well.

This will continue into Q4 by which time we anticipate nearing our historic manufacturing efficiencies. So what's coming in Q3, let me have Jack Glenn, our CFO, detail this for you, but I will say that as we enter Q3 with a solid backlog of our pump and monitor systems as well as a strong backlog of FMD systems, We, again, however, will be in a controlled production ramp phase, though ramping from 130 to our Q3 production target of over 300 3870 pumps is certainly a very high ramp rate. The team is performing, and we will feel -- and we feel confident we will deliver along with ever more MRI patient monitoring systems as well.

Thus, you can expect IRadimed to be heading back to and beyond the strong growth rates of the past with expectations that by Q4 and with 2 early product launch quarters in the rearview, our gross margins will have not only returned but be setting new records, which fall directly to the bottom line, of course. Now I'll turn the call over to Jack Glenn, our CFO, to review the quarter's financial results and provide a deeper color on the growth through the balance of the year.

John Glenn: Thank you, Roger, and good morning, everyone. As in the past, our results are reported on a GAAP basis and a non-GAAP basis. You can find a description of our non-GAAP measures in this morning's earnings release and a reconciliation to GAAP on the last page. For the 3 months ended June 30, 2026, revenue was $20.5 million, up 0.5% from $20.4 million in the second quarter of 2025. Pump revenue was in line with our expectations as we transitioned from the 3860 to the next-generation 3870 pump. MRI compatible patient vital signs monitoring systems contributed $6.7 million, up 12% year-over-year, and Ferro-magnetic Detection System contributed $0.8 million, up 57%.

On the recurring side, disposables grew revenue -- disposables revenue grew 14% to $4.8 million, driven by continued increases in device utilization, amortization of extended maintenance agreements grew 28% to $0.8 million and services and other grew 7% to $1.1 million. Domestic sales were 82% of total revenue in the second quarter compared to 89% a year earlier as domestic 3860 pump revenues were exceptionally strong in Q2 of last year. For the 6 months, domestic sales accounted for 82% of revenue, down from 86% a year ago. Gross profit for the quarter was $15.2 million with a margin of 74% compared with $16 million and 78% in the second quarter of 2025.

The decline in gross margin reflects the higher manufacturing costs associated with our first sizable production ramp of the 3870. For the 6 months, gross profit was $32 million with a margin of 75%, down from 77% a year earlier. We expect the gross margin to improve in the second half of the year as 3870 volumes build and manufacturing efficiencies take hold. Total operating expenses for the quarter were $8.8 million, down 4% from $9.2 million and 43% of revenue compared with 45% a year ago. General and administrative expense was $3.9 million, down 10%, primarily due to lower legal and professional fees, regulatory consulting and payroll and benefits.

Sales and marketing expense was $4.2 million, up 6%, primarily due to higher sales commissions driven by the strong bookings in the quarter. Research and development expense was $0.7 million, down 25%, primarily reflecting an increase in capitalized internal software development on the next-generation monitor in the quarter. Income from operations for the quarter was $6.4 million or 31% of revenue compared with $6.8 million a year ago. Tax expense for the quarter was $1.7 million, with an effective tax rate of 24.2% compared with a 21.2% rate in the second quarter of 2025. The rate differs from the U.S. federal statutory rate, primarily due to state income tax expense, partially offset by benefits from research and development tax credits.

As we stated in our first quarter call, the effective tax rate is also affected by the timing of deductions tied to the windfall deduction for equity grants, which is a discrete item taken at the time of vesting of the equity grants, most of which occur in the fourth quarter of the year. We no longer expect the windfall deduction to be as large as we originally thought, and therefore, believe the effective tax rate will be likely in the 24% range for the remainder of the year. Net income for the quarter was $5.2 million or $0.41 per diluted share compared with $5.8 million or $0.45 per diluted share.

Non-GAAP net income was $5.9 million or $0.46 per diluted share compared with $6.4 million or $0.49 per diluted share, excluding $0.6 million of stock-based compensation expense net of tax benefit. For the 6 months, net income was $11 million or $0.86 per diluted share, up 5% and non-GAAP net income was $12.2 million or $0.95 per diluted share, up 4%. We ended the quarter with cash and cash equivalents of $59.1 million, up from $51.2 million at year-end. Cash flow from operations was $5.9 million for the quarter and $14.2 million for the 6 months, an increase of 18% over the first half of last year.

Capital expenditures were $0.4 million for the quarter and $0.9 million for the 6 months, down from $6.7 million in the prior year period, which had included the construction of our new corporate office and manufacturing facility. Non-GAAP free cash flow was $5.5 million for the quarter and $13.3 million for the 6 months. Also, our Board of Directors declared a quarterly cash dividend of $0.20 per share payable on August 28, 2026, to stockholders of record as of the close of business on August 14, 2026. And lastly, to repeat our guidance.

For the third quarter of we expect revenue of $23 million to $24.5 million, GAAP diluted earnings per share of $0.49 to $0.54 and non-GAAP diluted earnings per share of $0.54 to $0.59. For the full year 2026, we reaffirm our guidance and expect revenue of $91 million to $96 million, GAAP diluted earnings per share of $1.90 to $2.05 and non-GAAP diluted earnings per share of $2.09 to $2.24. Our non-GAAP earnings per share guidance excludes stock-based compensation expense and net of tax, which we expect to be approximately $2.5 million for the full year. And with that, I will turn the call over to questions. Operator?

Operator: [Operator Instructions] Our first question comes from the line of Frank Takkinen with Lake Street Capital Markets.

Nelson Cox: This is Nelson on for Frank. I want to start with the 3870 ramp. You went from 0 to 130-plus pumps in Q2 and now are planning for over 300 in Q3. I mean can you talk a little bit more about what that requires operationally? And are you adding additional shifts or production headcount, or does the existing line gets you there? And does the pace keep stepping up in Q4? Or should we kind of -- or how are you kind of wanting us to think about that?

Roger Susi: No, we're not -- we kind of did the staffing stuff over the previous several months anticipating exactly what we need to meet the demands of making a new pump. So we're no longer doing that. That's -- so those expenses those had been in place, and that's not where we're going. It's exactly what I mentioned a few times over. It's strictly learning curve. It's experience, it's the efficiencies come when the folks that are making these products, basically they becomes sort of second nature, muscle memory, what have you, that's the experience I'm talking about. So it's -- at this point, cost-wise, free.

But time-wise, they look to work over time to do this learning, and they're not as efficient and as fast.

Nelson Cox: Helpful. And then as your 3860 units are phasing out, what happens -- how should we think about the service and disposable revenue attached to that install base. Maybe just talk through the 3870 quad replacement and your expectations with that for recurring revenue per site as those phase out. Is there any kind of transition gap you're thinking about? Or should we not really see anything like that?

John Glenn: Yes, I can take that one, maybe. As far as the disposal revenue, you're seeing some nice growth already, right? I think in the quarter, had over 14% growth on the disposables, so the 3860 installed base continues, hopefully, on the same kind of utilization. What we're really excited about and we think will help us even grow that more in the future is the quad stack. Of course, we're seeing, right? That should help us really drive utilization just as you see 4 pumps compared to 2, so we're excited about the opportunity there, I think, in the future on the 3870 and the utilization.

Nelson Cox: Got it. And then maybe just last one. If you're a hospital -- say, a hospital signs a quad stack order today, when are you kind of expecting that shift. Our new bookings landing maybe in Q4? Is it -- are we pushing into Q1 of next year? Or how is that playing out?

John Glenn: As far as lead time?

Nelson Cox: Yes, as far as lead time goes.

John Glenn: I think as far as lead times, we're able to right now probably get it within the next quarter kind of thing, probably or at least orders that are coming in fill within 3 months.

Roger Susi: Yes. So I mean, our -- our bookings of the new pump were more than doubled what we shipped. So the backlog is building. And as we go through the coming quarters, I wasn't quite sure of your question.

But as we go through the coming quarters, of course, there'll be what customers experience as the lead time will extend back out to more historic levels, which is -- we've had lead times out in the 4 and 5 months zone on 6-month zone through much of our history and we're probably headed there and maybe a little more, frankly, because of the demand of this new system and because of the pleasant surprise of basically selling double the number of pumps with these quad systems.

Operator: Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Roger for closing remarks.

Roger Susi: Thank you, operator. Well, as you heard, with the excellent customer reception of the new 3870 IV pump and continued strong sales of a 3880 patient monitor, along with production experience growing pushing up our ability to ramp 3870s, our $100 million run rate in Q4 is now well within our grasp. So with that, I'd like to thank you all for joining today's call and look forward to ramping production and regaining efficiencies as we capitalize on this huge opportunity before us. Thank you.

Operator: Thank you. This concludes the call. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has positions in and recommends Iradimed Corporation. The Motley Fool has a disclosure policy.